{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:28Z","timestamp":1790266288126,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100735","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:16:26Z","timestamp":1785446186000},"page":"100735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1933-3131","authenticated-orcid":false,"given":"C.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0922-1227","authenticated-orcid":false,"given":"N.","family":"Stambaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4620","authenticated-orcid":false,"given":"C.","family":"Stambaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-5871","authenticated-orcid":false,"given":"K.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmorw.2026.100735_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100735_bib2","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.21037\/jtd-2024-2202","article-title":"Improvement of survival outcomes in patients with advanced-stage non-small-cell lung cancer treated with chemotherapy: a retrospective cohort study evaluating the role of immune checkpoint inhibitors","volume":"17","author":"Sakamori","year":"2025","journal-title":"J Thorac Dis"},{"issue":"18","key":"10.1016\/j.esmorw.2026.100735_bib3","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.3390\/cancers14184481","article-title":"Real-world outcomes and treatments patterns prior to and after the introduction of first-line immunotherapy for the treatment of metastatic non-small cell lung cancer","volume":"14","author":"Danesi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100735_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100735_bib5","series-title":"NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 3","year":"2025"},{"issue":"20","key":"10.1016\/j.esmorw.2026.100735_bib6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.esmorw.2026.100735_bib7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100735_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24478","article-title":"Immunotherapy after chemotherapy and radiation for clinical stage III lung cancer","volume":"5","author":"Pichert","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100735_bib9","doi-asserted-by":"crossref","first-page":"8190","DOI":"10.1038\/s41598-023-35216-2","article-title":"Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database","volume":"13","author":"Gupta","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100735_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CJI.0000000000000400","article-title":"Racial differences in survival among advanced-stage non-small-cell lung cancer patients who received immunotherapy: an analysis of the US National Cancer Database (NCDB)","volume":"45","author":"Gupta","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.esmorw.2026.100735_bib13","doi-asserted-by":"crossref","DOI":"10.2196\/44070","article-title":"The association between social determinants of health and population health outcomes: ecological analysis","volume":"9","author":"Vo","year":"2023","journal-title":"JMIR Public Health Surveill"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100735_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurpub\/ckaa095","article-title":"Social determinants of health and inequalities in COVID-19","volume":"30","author":"Burstr\u00f6m","year":"2020","journal-title":"Eur J Public Health"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100735_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jech.57.4.254","article-title":"Defining equity in health","volume":"57","author":"Braveman","year":"2003","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100735_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100735_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: A critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100735_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000521952","article-title":"Comorbidity: from a confounder in longitudinal clinical research to the main issue in population management","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.esmorw.2026.100735_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2020.104298","article-title":"Association between social isolation and outpatient follow-up in older adults following emergency department discharge","volume":"93","author":"Cayenne","year":"2021","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100735_bib21","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3747\/co.27.6047","article-title":"Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100735_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ACM.0000000000002027","article-title":"The more things change, the more they stay the same: a study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials","volume":"93","author":"Geller","year":"2018","journal-title":"Acad Med"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100735_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s10903-021-01142-6","article-title":"Asians and Asian subgroups are underrepresented in medical research studies published in high-impact generalist journals","volume":"23","author":"Nguyen","year":"2021","journal-title":"J Immigr Minor Health"},{"key":"10.1016\/j.esmorw.2026.100735_bib24","series-title":"Asian Americans are the fastest-growing racial or ethnic group in the U.S","author":"Budiman","year":"2021"},{"issue":"13","key":"10.1016\/j.esmorw.2026.100735_bib25","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/cncr.28695","article-title":"The 2014 Surgeon General\u2019s report: \u201cThe health consequences of smoking\u201450 years of progress\u201d: a paradigm shift in cancer care","volume":"120","author":"Warren","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100735_bib26","first-page":"405","article-title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019","volume":"74","author":"Islami","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100735_bib27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.29812","article-title":"Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the Lung Cancer Mutation Consortium","volume":"122","author":"Steuer","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.esmorw.2026.100735_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107378","article-title":"Prevalence of oncogenic driver mutations in Hispanics\/Latin patients with lung cancer. A systematic review and meta-analysis","volume":"185","author":"Parra-Medina","year":"2023","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100735_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cllc.2025.02.008","article-title":"Racial diversity and co-mutational analysis of biologically relevant alterations in EGFR mutant lung cancers","volume":"26","author":"Gutta","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100735_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2767-9764.CRC-24-0504","article-title":"Real-world incidence of anaplastic lymphoma kinase alterations in Hispanics with non-small cell lung cancer at a large academic institution in Los Angeles","volume":"5","author":"Poei","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100735_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:40:43Z","timestamp":1790264443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S2949820126000548"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100735","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100735"}}